2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Advanced Cancer
1
Interventions
pembrolizumab
29
avelumab
21
Nivolumab
20
Ipilimumab
10
Radiotherapy
9
Cyclophosphamide
9
atezolizumab
8
cemiplimab
7
fludarabine
6
Specimen Handling
6
durvalumab
5
aldesleukin
5
Radiation
5
Magnetic Resonance Spectroscopy
5
Interleukin-2
5
Biopsy
5
talimogene laherparepvec
4
ALT-803
4
poly ICLC
3
Radiosurgery
3
Etoposide
3
Cisplatin
3
Carboplatin
3
CTLA-4 Antigen
3
Bevacizumab
3
prednylidene
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
domatinostat
2
deltacortene
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
bempegaldesleukin
×
Clear all
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts